Bedrijfsoverzicht
Pomdoctor Limited, via its diverse subsidiaries, operates a business model centered on the provision of an online B2C portal dedicated to the sale of pharmaceutical products, alongside the development of a specialized online medical services platform targeting chronic disease management within the Chinese market. The enterprise functions within the broader Healthcare sector and specifically occupies the Pharmaceutical Retailers industry, positioning it as a key player in the digitalization of medical services and chronic care delivery. This entity employs a workforce of 156 individuals and maintains a market capitalization of $36.38M while reporting a Trailing Twelve Months (TTM) revenue of $366.86M. The disparity between the substantial revenue figure of $366.86M and the relatively modest market cap of $36.38M indicates a significant market discount, suggesting that the market values the company's future growth potential or current profitability constraints differently than its top-line sales volume would traditionally imply for a peer in the pharmaceutical retail space.
Financiële gezondheid
Pomdoctor Limited reported a Total Revenue of $366.86M over the trailing twelve months, yet simultaneously recorded a Net Income of -$148,901,728 and an EBITDA of -$25,949,008, revealing a cost structure where expenses heavily outweigh gross earnings. The company's Free Cash Flow stands at -$12,435,489, which signifies a negative financial flexibility where operational cash outflows exceed cash inflows, requiring reliance on existing liquidity or external financing to sustain operations. Analyzing the profit margins provides insight into the company's efficiency: the Gross Margin is 14.1%, indicating that after direct costs of goods sold, the company retains a modest portion of revenue; however, the Operating Margin of -6.5% and Profit Margin of -40.6% demonstrate that high overhead costs or operating expenses are eroding profitability significantly. Regarding liquidity and leverage, the company holds $5.75M in cash against a total debt load of $456.02M, creating a precarious situation where debt obligations vastly exceed liquid assets, and the absence of a listed Debt to Equity ratio further underscores the leverage intensity relative to equity. The Current Ratio is calculated at 0.17, a figure that indicates severe short-term liquidity constraints as current liabilities exceed current assets, potentially hindering the ability to meet immediate financial obligations without asset sales or refinancing. Furthermore, the Return on Equity is listed as N/A due to the capital structure, while the Return on Assets is -32.6%, a metric that reveals that the company's assets are generating negative returns, reflecting a lack of management effectiveness in deploying capital profitably given the current operational losses.
Waarderingsbeoordeling
The valuation metrics for Pomdoctor Limited present a complex picture, with the P/E Ratio (TTM) and Forward P/E both listed as N/A due to the company's negative net income, which prevents the calculation of traditional earnings multiples and implies that earnings-based valuation models are currently inapplicable. The Price to Book ratio is recorded at -0.03, a negative figure that suggests the market is pricing the company below its book value, a scenario often associated with distressed assets or entities with significant liabilities that outweigh their tangible equity. Alternative valuation metrics such as the Price to Sales ratio of 0.10 and the EV/EBITDA of -87.42 indicate that the market is pricing the company at a fraction of its sales revenue and at a negative multiple of earnings before interest, taxes, and depreciation, reflecting deep skepticism regarding immediate earnings generation. In terms of trading range, the stock has a 52-Week High of $6.43 and a 52-Week Low of $0.19; without a specific current share price provided in the source data to calculate a precise percentage, the wide range of $6.24 between the high and low highlights the extreme volatility experienced by the stock over the last year. The Beta is listed as N/A, meaning that the specific volatility relative to the broader market index cannot be quantified from the available data points, though the wide 52-week price spread itself serves as a proxy for high idiosyncratic risk.
Growth & Income
Pomdoctor Limited has demonstrated robust top-line expansion with a Revenue Growth (YoY) of 16.2%, whereas the Earnings Growth (YoY) is N/A due to the company reporting a Net Income of -$148,901,728, meaning that while sales are increasing, profitability has not yet materialized to generate growth in earnings. As a non-dividend payer with a Dividend Yield of N/A and a Payout Ratio of 0.0%, the company does not distribute cash to shareholders, which aligns with its strategy of retaining all earnings and cash flow to fund operations or reduce debt rather than rewarding investors with income. The combination of strong revenue growth coupled with persistent negative earnings and a significant cash burn rate suggests that the company is in an investment phase where capital is being deployed to capture market share or develop its chronic disease management platform rather than delivering immediate financial returns. Overall, the growth and income profile is characterized by high revenue velocity but a complete absence of current profitability or income distribution, positioning the stock as a high-risk, high-potential growth candidate dependent on a future turnaround in net income to justify its current market valuation.